Dementia Researcher

Dr Sam Moxon has been working on a new grant and exploring how to create a spin out innovation biotech company. This work led him to meet Matthias Alder, who we just had to get on the podcast. In this show we hear from Gain Therapeutics CEO Matthias Alder. He is leading a biotech company engaged in the development of a potentially disease-modifying therapy for the treatment of neurodegenerative diseases. Hoping to unlock new treatments for difficult to treat disorders with their SEE-Tx™ supercomputer-driven, drug discovery platform targeting allosteric binding sites. There is a lot of work underway to explore modifying enzymes that have misfolded, losing their functional structure. Misfolding can lead to various diseases, including neurodegenerative disorders like Alzheimer's and Parkinson's. Researchers in this field seek, and Gain Therapeutics study the mechanisms behind enzyme misfolding, explore the consequences of misfolding on cellular functions, and develop strategies to correct or reshape these misfo